Physician profile
Alan R Dayan
NPI 1437180775
$2,279.26
in general payments reported to CMS, 2019-2025
14 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2022: $328 · 2023: $596 · 2024: $618 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $568.44 | 2019-2024 | Clareon |
| Regeneron Healthcare Solutions, INC. | $403.01 | 2023-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $258.59 | 2023-2025 | Ozurdex |
| Carl Zeiss Meditec Cataract Technology INC. | $192.37 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $159.60 | 2022-2024 | Tecnis Simplicity |
| Apellis Pharmaceuticals, INC. | $132.80 | 2023-2025 | Syfovre |
| Shire North American Group INC | $126.30 | 2019 | |
| Mallinckrodt Hospital Products INC. | $92.51 | 2022-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $87.94 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $80.53 | 2025 | Yutiq, Iluvien |
| Bausch & Lomb Americas INC. | $60.17 | 2023-2024 | Xipere, Lotemax Sm, Visudyne |
| Astellas Pharma US INC | $55.24 | 2024-2025 | Izervay |
| Alimera Sciences, INC. | $40.53 | 2023 | Iluvien |
| Eyepoint US, INC. | $21.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Dayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.